YUNNAN BOTANEE BIO-TECHNOLOGY GROUP CO.LTD

Yunnan Botanee Bio-Technology Group Co.LTD

300957

CNE100004G74

Personal Products

End-of-day quote Shenzhen S.E. Other stock markets 2025-06-16			5-day change	1st Jan Change
45.83 ^CNY	-0.50%		-3.64%	+7.36%

May. 16	Yunnan Botanee Bio-Technology Group Co.LTD Approves Board Appointments	CI
May. 06	A group of buyers completed the acquisition of 2.50% stake in Yunnan Botanee Bio-Technology Group Co.LTD from Tianjin Sequoia Juye Equity Investment Partnership Enterprise (Limited Partnership), Kunming Zhenli Consulting Co., Ltd. and HongShan for CNY 350 million.	CI

A group of buyers completed the acquisition of 2.50% stake in Yunnan Botanee Bio-Technology Group Co.LTD from Tianjin Sequoia Juye Equity Investment Partnership Enterprise (Limited Partnership), Kunming Zhenli Consulting Co., Ltd. and HongShan for CNY 350 million.

Published on 05/06/2025 at 18:00

UBS Group AG (SWX:UBSG), Beijing Pingfan Private Equity Fund Management Co., Ltd., Beijing dao-fund Asset Management Co., Ltd., Caitong Fund Management Co., Ltd., Guotai Haitong Securities Co., Ltd. (SHSE:601211), Guotai Junan Financial Holdings Co., Ltd., Nanjing Shengquan Hengyuan Investment Co., Ltd., Ningbo Meishan Bonded Port Lingding Investment Management Co., Ltd., Nuode Asset Management Co., Ltd., Qingdao Luxiu Investment Management Co., Ltd., Shanghai Muxin Private Fund Management Co., Ltd., Yingshui Investment Co., Ltd., CITIC Futures Co., Ltd. and GF Securities Co., Ltd. (SZSE:000776) agreed to acquire 2.50% stake in Yunnan Botanee Bio-Technology Group Co.LTD (SZSE:300957) from Tianjin Sequoia Juye Equity Investment Partnership Enterprise (Limited Partnership), Kunming Zhenli Consulting Co., Ltd. and HongShan for CNY 350 million on May 7, 2025. A cash consideration of CNY 350.73 million valued at CNY 33.3 per share will be paid by UBS Group AG, Beijing Pingfan Private Equity Fund Management Co., Ltd., Beijing dao-fund Asset Management Co., Ltd., Caitong Fund Management Co., Ltd., Guotai Haitong Securities Co., Ltd., Guotai Junan Financial Holdings Co., Ltd., Nanjing Shengquan Hengyuan Investment Co., Ltd., Ningbo Meishan Bonded Port Lingding Investment Management Co., Ltd., Nuode Asset Management Co., Ltd., Qingdao Luxiu Investment Management Co., Ltd., Shanghai Muxin Private Fund Management Co., Ltd., Yingshui Investment Co., Ltd., CITIC Futures Co., Ltd. and GF Securities Co., Ltd. As part of consideration, CNY 350.73 million is paid towards common equity of Yunnan Botanee Bio-Technology Group Co.LTD.

UBS Group AG (SWX:UBSG), Beijing Pingfan Private Equity Fund Management Co., Ltd., Beijing dao-fund Asset Management Co., Ltd., Caitong Fund Management Co., Ltd., Guotai Haitong Securities Co., Ltd. (SHSE:601211), Guotai Junan Financial Holdings Co., Ltd., Nanjing Shengquan Hengyuan Investment Co., Ltd., Ningbo Meishan Bonded Port Lingding Investment Management Co., Ltd., Nuode Asset Management Co., Ltd., Qingdao Luxiu Investment Management Co., Ltd., Shanghai Muxin Private Fund Management Co., Ltd., Yingshui Investment Co., Ltd., CITIC Futures Co., Ltd. and GF Securities Co., Ltd. (SZSE:000776) completed the acquisition of 2.50% stake in Yunnan Botanee Bio-Technology Group Co.LTD (SZSE:300957) from Tianjin Sequoia Juye Equity Investment Partnership Enterprise (Limited Partnership), Kunming Zhenli Consulting Co., Ltd. and HongShan for CNY 350 million on May 7, 2025.

Stocks mentioned in the article

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
YUNNAN BOTANEE BIO-TECHNOLOGY GROUP CO.LTD	45.83CNY	-0.50%	-3.64%	2.65B
UBS GROUP AG	25.84CHF	-1.07%	-2.60%	97.32B
GUOTAI HAITONG SECURITIES CO., LTD.	18.43CNY	+1.26%	-0.38%	41.89B
GF SECURITIES CO., LTD.	16.87CNY	+1.26%	+2.55%	16.62B

Latest news about Yunnan Botanee Bio-Technology Group Co.LTD

Yunnan Botanee Bio-Technology Group Co.LTD Approves Board Appointments	May. 16	CI
A group of buyers completed the acquisition of 2.50% stake in Yunnan Botanee Bio-Technology Group Co.LTD from Tianjin Sequoia Juye Equity Investment Partnership Enterprise (Limited Partnership), Kunming Zhenli Consulting Co., Ltd. and HongShan for CNY 350 million.	May. 06	CI
Jefferies Adjusts Yunnan Botanee Bio-Technology's Price Target to 42 Yuan From 62 Yuan, Keeps at Hold	Apr. 28	MT
Yunnan Botanee Bio-Technology Group Co.LTD Reports Earnings Results for the First Quarter Ended March 31, 2025	Apr. 24	CI
Yunnan Botanee Bio-Technology's Parent, Shareholder to Divest Stake	Nov. 11	MT
Yunnan Botanee Bio-Technology Group Co.LTD Reports Earnings Results for the Nine Months Ended September 30, 2024	24-10-24	CI
Tranche Update on Yunnan Botanee Bio-Technology Group Co.LTD's Equity Buyback Plan announced on August 30, 2023.	24-08-30	CI
Yunnan Botanee Bio-Technology Group Co.LTD's Equity Buyback announced on August 30, 2023 has closed with 3,649,618 shares, representing 0.87% for CNY 234.72 million.	24-08-29	CI
Yunnan Botanee Bio-Technology Group Co.LTD Reports Earnings Results for the Half Year Ended June 30, 2024	24-08-27	CI
Tranche Update on Yunnan Botanee Bio-Technology Group Co.LTD's Equity Buyback Plan announced on August 30, 2023.	24-07-01	CI
Jefferies Adjusts Yunnan Botanee Bio-Technology’s Price Target to 62 Yuan From 87 Yuan, Keeps at Hold	24-04-29	MT
Yunnan Botanee Bio-Technology Group Co.LTD Reports Earnings Results for the First Quarter Ended March 31, 2024	24-04-25	CI
Yunnan Botanee Bio-Technology Group Co.LTD Reports Earnings Results for the Full Year Ended December 31, 2023	24-04-25	CI
Tranche Update on Yunnan Botanee Bio-Technology Group Co.LTD's Equity Buyback Plan announced on August 30, 2023.	24-04-01	CI
Certain A Shares of Yunnan Botanee Bio-Technology Group Co.LTD are subject to a Lock-Up Agreement Ending on 25-MAR-2024.	24-03-24	CI
Weimai Medical Technology Co., Ltd. announced that it has received funding from CDH Investment Management Company Limited, Yunnan Botanee Bio-Technology Group Co.LTD	24-03-14	CI
Weimai Qingtong Medical Technology Co., Ltd. announced that it has received funding from CDH Investment Management Company Limited, Changzhou Lizhong Investment Management Co., Ltd., Yunnan Botanee Bio-Technology Group Co.LTD, Guangdong Evergreen Conglomerate Co., Ltd.	24-03-12	CI
Tranche Update on Yunnan Botanee Bio-Technology Group Co.LTD's Equity Buyback Plan announced on August 30, 2023.	24-01-02	CI
In China's slowing beauty market, big brand discounts won't cut it	23-12-07	RE
Shanghai Weimu Medical Technology Co., Ltd. announced that it has received CNY 100 million in funding from Yunnan Botanee Bio-Technology Group Co.LTD, Huajin Avenue Investment Co., Ltd., SHAREWIN Equity Investment and Management Co., Ltd., Shanghai CS Capital Co., Ltd, Sinvo Capital Holdings Co., Ltd., Investment Arm, IDG Capital Partners Co., Ltd.	23-12-05	CI
Jefferies Adjusts Yunnan Botanee Bio-Technology’s Price Target to 87 Yuan From 105 Yuan, Keeps at Hold	23-10-31	MT
Yunnan Botanee Bio-Technology Group Co.LTD Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-29	CI
Yunnan Botanee Bio-Technology Group Co.LTD announces an Increase in Equity Buyback.	23-10-26	CI
Weimai Medical Technology Co., Ltd. announced that it has received funding from Yunnan Botanee Bio-Technology Group Co.LTD	23-10-26	CI
Yunnan Botanee Bio-Technology Group Co.LTD announces an Equity Buyback for CNY 200 million worth of its shares.	23-08-30	CI

Chart Yunnan Botanee Bio-Technology Group Co.LTD

Duration

Period

Chart Yunnan Botanee Bio-Technology Group Co.LTD

300957: Dynamic Chart

Company Profile

Yunnan Botanee Bio-Technology Group Co LTD is a Chinese company mainly engaged in the production of cosmetics. The Company adopts a sales model based on offline channel sales and online channel sales as the leading factor. The Company's products mainly include creams, skin care lotions, facial masks, essences, lotions and other skin care products and make-up products such as isolation creams, blemish balm (BB) creams, and makeup removers. The Company is also engaged in the research and development, production and sales of skin care-related medical device products, mainly including hyaluronic acid repairing biofilm, hyaluronic acid repairing dressings, mainly used for the protection of skin with damaged barriers after minimally invasive surgery and care.

Employees

3,956

Sector

Personal Products

Calendar

Sep. 01 - Q2 2025 Earnings Release (Projected)

More about the company